RYTM
$87.55-2.97 (-3.28%)
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
Recent News
Rhythm Pharmaceuticals Misses The Beat In Obesity, But There's A Caveat
Shares of Rhythm Pharmaceuticals wavered Tuesday after the biotech's experimental weight-loss drug missed its mark in a yearlong study.
Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial
March 16 (Reuters) - Rhythm Pharmaceuticals said on Monday its experimental obesity drug in patients with rare genetic conditions did not meet the main goal of a late-stage trial.
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.
Rhythm Pharmaceuticals price target lowered to $110 from $125 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $110 from $125 and keeps a Buy rating on the shares, reflecting adjustments to the firm’s long-term sales ramp expectations after Rhythm recently announced its Q4 results and announced additional positive data from its global Phase 3 TRANSCEND trial of setmelanotide in patients with acquired hypothalamic obesity.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, s
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After Recent Pullback In Share Price
Rhythm Pharmaceuticals overview after recent trading move Rhythm Pharmaceuticals (RYTM) has come into focus after a recent pullback in its share price, with the stock closing at US$92.73 and showing negative returns over the past week and month. See our latest analysis for Rhythm Pharmaceuticals. That short term weakness, with a 1 day share price return of 5.45% decline and a 30 day share price return of 9.55% decline, sits against a very strong backdrop, including a 1 year total shareholder...